AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig

AbbVie presented long-term data from Phase 3 studies showing continued facial and total-body repigmentation with RINVOQ in non-segmental vitiligo patients through Week 76. The safety profile remained consistent. The company also reported early data supporting RINVOQ's combination with NB-UVB phototherapy. ABBV stock is currently trading at $259.87, down 0.68%.

AbbVie won a partial dismissal in a US antitrust case over Humira, with a judge ruling that plaintiffs cannot seek damages as indirect purchasers. However, claims for injunctive relief were maintained, as the judge found it plausible that AbbVie's actions substantially foreclosed competitors. The case involves agreements with pharmacy benefit managers to favor Humira on formularies.

AbbVie's phase 3 studies show Rinvoq (upadacitinib) improved facial and total body repigmentation in vitiligo patients at week 76. Viti-Up-1 reported 55.1% and 42.5% reductions, while Viti-Up-2 reported 47.4% and 40.1%. AbbVie seeks FDA and EMA approval, with a decision expected in Q4. Rinvoq gained EU approval in July.

AbbVie (NYSE:ABBV) presented Phase 3 study data at the 2026 EADV Congress, showing improved repigmentation in vitiligo patients treated with RINVOQ through 76 weeks. The data indicated increased facial and total body repigmentation. Combining RINVOQ with phototherapy showed higher response rates. RINVOQ is approved in the EU for vitiligo and is under FDA review in the U.S.

AbbVie presented Phase 3 data showing RINVOQ's continued repigmentation benefits in non-segmental vitiligo through 76 weeks, with additional improvements when combined with NB-UVB phototherapy. Presented at the 2026 EADV Congress, the findings support RINVOQ's long-term use and potential combination therapies. RINVOQ is approved in the EU for vitiligo and under U.S. review.

AbbVie (NYSE:ABBV) reported positive Phase 2 data for zumilokibart in treating atopic dermatitis, showing significant skin clearance and itch reduction. It also presented Phase 1 results for ABBV-295, its weight-loss candidate, with dose-dependent weight reductions of -7.8% to -9.8% over 12-13 weeks. ABBV shares were up 0.16% to $263.71 at the time of publication.